Euglena（2931）株式概要株式会社ユーグレナは、日本で微細藻類の研究・開発・生産・販売を行っている。 詳細2931 ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長3/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より26.7%で取引されている 収益は年間52.28%増加すると予測されています 過去5年間の収益は年間22.2%増加しました。 同業他社や業界と比較して、良好な取引価格 リスク分析リスクチェックの結果、2931 、リスクは検出されなかった。すべてのリスクチェックを見る2931 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥328.0040.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b58b2016201920222025202620282031Revenue JP¥57.9bEarnings JP¥6.2bAdvancedSet Fair ValueView all narrativesEuglena Co., Ltd. 競合他社ShinnihonseiyakuSymbol: TSE:4931Market cap: JP¥41.2bCotaSymbol: TSE:4923Market cap: JP¥30.2bArtnatureSymbol: TSE:7823Market cap: JP¥28.0bMilbonSymbol: TSE:4919Market cap: JP¥83.7b価格と性能株価の高値、安値、推移の概要Euglena過去の株価現在の株価JP¥328.0052週高値JP¥513.0052週安値JP¥332.00ベータ-0.0891ヶ月の変化-9.39%3ヶ月変化-11.11%1年変化-22.27%3年間の変化-63.06%5年間の変化-62.90%IPOからの変化109.72%最新ニュースお知らせ • Jun 01Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥358. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.Board Change • Apr 09Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Mirai Murakami was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 27Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Mar 12Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.1% to JP¥368. The fair value is estimated to be JP¥462, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 55%.Reported Earnings • Feb 16Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.最新情報をもっと見るRecent updatesお知らせ • Jun 01Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥358. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.Board Change • Apr 09Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Mirai Murakami was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 27Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Mar 12Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.1% to JP¥368. The fair value is estimated to be JP¥462, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 55%.Reported Earnings • Feb 16Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.お知らせ • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: JP¥1.31 (vs JP¥1.40 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥1.31 (up from JP¥1.40 loss in 3Q 2024). Revenue: JP¥12.5b (up 4.6% from 3Q 2024). Net income: JP¥179.0m (up JP¥370.5m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • Sep 03Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025お知らせ • Aug 19Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2025Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2025. For the year, the company expects net sales of JPY 50,000 million and operating profit of JPY 2,400 million.Reported Earnings • Aug 09Second quarter 2025 earnings released: JP¥0.38 loss per share (vs JP¥3.37 loss in 2Q 2024)Second quarter 2025 results: JP¥0.38 loss per share (improved from JP¥3.37 loss in 2Q 2024). Revenue: JP¥12.6b (up 1.0% from 2Q 2024). Net loss: JP¥52.0m (loss narrowed 89% from 2Q 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Japan.分析記事 • Jul 28Here's Why Euglena (TSE:2931) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jun 03Euglena Co., Ltd. to Report Q2, 2025 Results on Aug 08, 2025Euglena Co., Ltd. announced that they will report Q2, 2025 results on Aug 08, 2025Reported Earnings • May 13First quarter 2025 earnings released: JP¥3.72 loss per share (vs JP¥1.48 profit in 1Q 2024)First quarter 2025 results: JP¥3.72 loss per share (down from JP¥1.48 profit in 1Q 2024). Revenue: JP¥11.9b (up 7.0% from 1Q 2024). Net loss: JP¥507.0m (down 365% from profit in 1Q 2024). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in Japan.分析記事 • Apr 15Euglena (TSE:2931) Has A Pretty Healthy Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Mar 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.分析記事 • Mar 19Returns At Euglena (TSE:2931) Are On The Way UpIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...お知らせ • Mar 01Euglena Co., Ltd. to Report Q1, 2025 Results on May 12, 2025Euglena Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025分析記事 • Feb 18The Market Lifts Euglena Co., Ltd. (TSE:2931) Shares 30% But It Can Do MoreEuglena Co., Ltd. ( TSE:2931 ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 16Full year 2024 earnings released: JP¥4.84 loss per share (vs JP¥22.75 loss in FY 2023)Full year 2024 results: JP¥4.84 loss per share (improved from JP¥22.75 loss in FY 2023). Revenue: JP¥47.6b (up 2.4% from FY 2023). Net loss: JP¥650.0m (loss narrowed 76% from FY 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Feb 14Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025.お知らせ • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025Euglena Co., Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025Reported Earnings • Nov 13Third quarter 2024 earnings released: JP¥5.73 loss per share (vs JP¥2.98 loss in 3Q 2023)Third quarter 2024 results: JP¥5.73 loss per share (further deteriorated from JP¥2.98 loss in 3Q 2023). Revenue: JP¥11.6b (up 3.1% from 3Q 2023). Net loss: JP¥781.0m (loss widened 124% from 3Q 2023). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.分析記事 • Nov 13Would Euglena (TSE:2931) Be Better Off With Less Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Aug 27Euglena Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024Euglena Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024お知らせ • Aug 14Euglena Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. revised consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 48,000 million.New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).お知らせ • Jun 02Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024Euglena Co., Ltd. announced that they will report Q2, 2024 results on Aug 08, 2024お知らせ • May 17Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 52,500 million.Reported Earnings • May 16First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥1.48 (up from JP¥1.45 loss in 1Q 2023). Revenue: JP¥11.2b (up 2.9% from 1Q 2023). Net income: JP¥191.0m (up JP¥358.0m from 1Q 2023). Profit margin: 1.7% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 29Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Euglena Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024Reported Earnings • Mar 27Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024.Reported Earnings • Feb 16Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.お知らせ • Jan 25Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million on January 24, 2024. As part of acquisition, 480 shares will be acquired for ¥0.75 million. The transaction is expected to complete on January 31, 2024.お知らせ • Jan 12Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd. on January 10, 2024.Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. Independent Outside Director Aiko Mochizuki was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 05Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024Euglena Co., Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024Reported Earnings • Nov 15Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)Third quarter 2023 results: JP¥2.98 loss per share (improved from JP¥15.91 loss in 3Q 2022). Revenue: JP¥11.3b (down 6.5% from 3Q 2022). Net loss: JP¥349.0m (loss narrowed 81% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.お知らせ • Sep 02Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023Euglena Co., Ltd. announced that they will report Q3, 2023 results on Nov 13, 2023Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: JP¥6.38 loss per share. Net loss: JP¥747.0m (flat on 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 4.2% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat.お知らせ • Jun 28Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023Euglena Co., Ltd. announced that they will report Q2, 2023 results on Aug 14, 2023Reported Earnings • May 17First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥1.45 loss per share. Net loss: JP¥167.0m (flat on 1Q 2022). Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year.Reported Earnings • Mar 31Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 12% per year.Price Target Changed • Mar 24Price target increased by 11% to JP¥1,000Up from JP¥900, the current price target is provided by 1 analyst. New target price is 10% above last closing price of JP¥906. Stock is up 10% over the past year. The company is forecast to post a net loss per share of JP¥11.50 next year compared to a net loss per share of JP¥23.83 last year.お知らせ • Feb 16Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023Euglena Co., Ltd. provided consolidated earnings guidance for the fiscal year ending Dec. 31, 2023. The company expects net sales to be JPY 45,000 million.お知らせ • Feb 15Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023.Reported Earnings • Feb 14Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 08Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.On February 6, 2023, Euglena Co., Ltd. closed the transaction.お知らせ • Jan 20Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.Euglena Co., Ltd. announced that it will issue 3,208,500 common shares at a price of ¥935 for gross proceeds of ¥2,999,947,500 and 48 convertible bond-type bonds with stock acquisition rights at a price of ¥100,000,000 for gross proceeds of ¥4,800,000,000 for aggregate gross proceeds of ¥4,785,000,000 on January 19, 2023. The transaction will include participation from Marui Group Co., Ltd. of 2,139,000 shares and Rohto Pharmaceutical Co.,Ltd. of 1,069,500 shares post completion of the transaction. The company is issuing securities through third party allotment. The 10th stock acquisition rights are convertible into 5,133,689 shares. The transaction is expected to close on February 6, 2023. The transaction has been approved by the board of directors of the company.お知らせ • Dec 28Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023Euglena Co., Ltd. announced that they will report fiscal year 2022 results on Feb 13, 2023Reported Earnings • Apr 02Full year 2021 earnings released: JP¥39.26 loss per share (vs JP¥17.15 loss in FY 2020)Full year 2021 results: JP¥39.26 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥27.5b (up 97% from FY 2020). Net loss: JP¥4.03b (loss widened 153% from FY 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 17Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥3.83b (up 34% from 2Q 2020). Net income: JP¥164.0m (up 51% from 2Q 2020). Profit margin: 4.3% (up from 3.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 16New 90-day high: JP¥1,264The company is up 58% from a price of JP¥799 on 16 December 2020. Outperformed the Japanese market which is up 10.0% over the last 90 days. Exceeded the Personal Products industry, which is flat over the same period.Reported Earnings • Feb 17First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥3.91b (up 22% from 1Q 2020). Net loss: JP¥360.0m (loss widened 43% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 05New 90-day high: JP¥909The company is up 4.0% from its price of JP¥871 on 06 November 2020. The Japanese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 2.0% over the same period.Reported Earnings • Dec 27Full year 2020 earnings released: JP¥16.00 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 23New 90-day low: JP¥774The company is down 16% from its price of JP¥917 on 24 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 5.0% over the same period.Is New 90 Day High Low • Dec 07New 90-day low: JP¥797The company is down 4.0% from its price of JP¥830 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.株主還元2931JP Personal ProductsJP 市場7D-3.0%0.6%4.7%1Y-22.3%-0.2%46.9%株主還元を見る業界別リターン: 2931過去 1 年間で-0.2 % の収益を上げたJP Personal Products業界を下回りました。リターン対市場: 2931は、過去 1 年間で46.9 % のリターンを上げたJP市場を下回りました。価格変動Is 2931's price volatile compared to industry and market?2931 volatility2931 Average Weekly Movement4.3%Personal Products Industry Average Movement3.7%Market Average Movement4.6%10% most volatile stocks in JP Market9.3%10% least volatile stocks in JP Market2.3%安定した株価: 2931 、 JP市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 2931の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005793Tomohiro Wakaharawww.euglena.jp株式会社ユーグレナは日本で微細藻類の研究、開発、生産、販売を行っている。事業セグメントは以下の通り：ヘルスケア事業、バイオ燃料事業、その他事業。ユーグレナやクロレラなどの微細藻類を利用した健康食品や化粧品を製造・販売している。また、微細藻類や産業廃油を利用したバイオ燃料技術や環境関連技術の開発、飼料・肥料事業、バイオインフォマティクス事業、ソーシャル事業からなるアグリ事業の開発・研究、バイオ関連事業への投資も行っている。また、ゲノム解析サービスも提供。株式会社ユーグレナは2005年に設立され、東京に本社を置く。もっと見るEuglena Co., Ltd. 基礎のまとめEuglena の収益と売上を時価総額と比較するとどうか。2931 基礎統計学時価総額JP¥46.87b収益（TTM）-JP¥330.00m売上高(TTM)JP¥51.63b0.9xP/Sレシオ-138.7xPER（株価収益率2931 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計2931 損益計算書（TTM）収益JP¥51.63b売上原価JP¥15.94b売上総利益JP¥35.69bその他の費用JP¥36.02b収益-JP¥330.00m直近の収益報告Mar 31, 2026次回決算日Aug 07, 2026一株当たり利益（EPS）-2.37グロス・マージン69.13%純利益率-0.64%有利子負債／自己資本比率82.5%2931 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.6%現在の配当利回り-83%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/22 18:52終値2026/06/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Euglena Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Shima YamanakaSMBC NIKKO
お知らせ • Jun 01Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026
Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥358. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.
Board Change • Apr 09Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Mirai Murakami was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 27Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Mar 12Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.1% to JP¥368. The fair value is estimated to be JP¥462, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 55%.
Reported Earnings • Feb 16Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Jun 01Euglena Co., Ltd. to Report Q2, 2026 Results on Aug 07, 2026Euglena Co., Ltd. announced that they will report Q2, 2026 results on Aug 07, 2026
Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥358. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 66%.
Board Change • Apr 09Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Mirai Murakami was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 27Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Mar 12Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.1% to JP¥368. The fair value is estimated to be JP¥462, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 55%.
Reported Earnings • Feb 16Full year 2025 earnings released: JP¥5.90 loss per share (vs JP¥4.84 loss in FY 2024)Full year 2025 results: JP¥5.90 loss per share (further deteriorated from JP¥4.84 loss in FY 2024). Revenue: JP¥50.4b (up 5.8% from FY 2024). Net loss: JP¥805.0m (loss widened 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026Euglena Co., Ltd., Annual General Meeting, Mar 24, 2026.
お知らせ • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026Euglena Co., Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: JP¥1.31 (vs JP¥1.40 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥1.31 (up from JP¥1.40 loss in 3Q 2024). Revenue: JP¥12.5b (up 4.6% from 3Q 2024). Net income: JP¥179.0m (up JP¥370.5m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • Sep 03Euglena Co., Ltd. to Report Q3, 2025 Results on Nov 13, 2025Euglena Co., Ltd. announced that they will report Q3, 2025 results on Nov 13, 2025
お知らせ • Aug 19Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2025Euglena Co., Ltd. provided consolidated earnings guidance for the year ending December 31, 2025. For the year, the company expects net sales of JPY 50,000 million and operating profit of JPY 2,400 million.
Reported Earnings • Aug 09Second quarter 2025 earnings released: JP¥0.38 loss per share (vs JP¥3.37 loss in 2Q 2024)Second quarter 2025 results: JP¥0.38 loss per share (improved from JP¥3.37 loss in 2Q 2024). Revenue: JP¥12.6b (up 1.0% from 2Q 2024). Net loss: JP¥52.0m (loss narrowed 89% from 2Q 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Japan.
分析記事 • Jul 28Here's Why Euglena (TSE:2931) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jun 03Euglena Co., Ltd. to Report Q2, 2025 Results on Aug 08, 2025Euglena Co., Ltd. announced that they will report Q2, 2025 results on Aug 08, 2025
Reported Earnings • May 13First quarter 2025 earnings released: JP¥3.72 loss per share (vs JP¥1.48 profit in 1Q 2024)First quarter 2025 results: JP¥3.72 loss per share (down from JP¥1.48 profit in 1Q 2024). Revenue: JP¥11.9b (up 7.0% from 1Q 2024). Net loss: JP¥507.0m (down 365% from profit in 1Q 2024). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in Japan.
分析記事 • Apr 15Euglena (TSE:2931) Has A Pretty Healthy Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Mar 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
分析記事 • Mar 19Returns At Euglena (TSE:2931) Are On The Way UpIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
お知らせ • Mar 01Euglena Co., Ltd. to Report Q1, 2025 Results on May 12, 2025Euglena Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025
分析記事 • Feb 18The Market Lifts Euglena Co., Ltd. (TSE:2931) Shares 30% But It Can Do MoreEuglena Co., Ltd. ( TSE:2931 ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...
New Risk • Feb 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 16Full year 2024 earnings released: JP¥4.84 loss per share (vs JP¥22.75 loss in FY 2023)Full year 2024 results: JP¥4.84 loss per share (improved from JP¥22.75 loss in FY 2023). Revenue: JP¥47.6b (up 2.4% from FY 2023). Net loss: JP¥650.0m (loss narrowed 76% from FY 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Feb 14Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025Euglena Co., Ltd., Annual General Meeting, Mar 28, 2025.
お知らせ • Dec 03Euglena Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025Euglena Co., Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025
Reported Earnings • Nov 13Third quarter 2024 earnings released: JP¥5.73 loss per share (vs JP¥2.98 loss in 3Q 2023)Third quarter 2024 results: JP¥5.73 loss per share (further deteriorated from JP¥2.98 loss in 3Q 2023). Revenue: JP¥11.6b (up 3.1% from 3Q 2023). Net loss: JP¥781.0m (loss widened 124% from 3Q 2023). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
分析記事 • Nov 13Would Euglena (TSE:2931) Be Better Off With Less Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Aug 27Euglena Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024Euglena Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024
お知らせ • Aug 14Euglena Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. revised consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 48,000 million.
New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding).
お知らせ • Jun 02Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024Euglena Co., Ltd. announced that they will report Q2, 2024 results on Aug 08, 2024
お知らせ • May 17Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024Euglena Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2024. for the year, the company expects Net sales of JPY 52,500 million.
Reported Earnings • May 16First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥1.48 (up from JP¥1.45 loss in 1Q 2023). Revenue: JP¥11.2b (up 2.9% from 1Q 2023). Net income: JP¥191.0m (up JP¥358.0m from 1Q 2023). Profit margin: 1.7% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 29Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Euglena Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024
Reported Earnings • Mar 27Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 16Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024.
Reported Earnings • Feb 16Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)Full year 2023 results: JP¥22.75 loss per share (improved from JP¥23.83 loss in FY 2022). Revenue: JP¥46.5b (up 4.7% from FY 2022). Net loss: JP¥2.65b (flat on FY 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 14% per year.
お知らせ • Jan 25Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million on January 24, 2024. As part of acquisition, 480 shares will be acquired for ¥0.75 million. The transaction is expected to complete on January 31, 2024.
お知らせ • Jan 12Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd. on January 10, 2024.
Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. Independent Outside Director Aiko Mochizuki was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 05Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024Euglena Co., Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024
Reported Earnings • Nov 15Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)Third quarter 2023 results: JP¥2.98 loss per share (improved from JP¥15.91 loss in 3Q 2022). Revenue: JP¥11.3b (down 6.5% from 3Q 2022). Net loss: JP¥349.0m (loss narrowed 81% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 02Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023Euglena Co., Ltd. announced that they will report Q3, 2023 results on Nov 13, 2023
Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: JP¥6.38 loss per share. Net loss: JP¥747.0m (flat on 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 4.2% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat.
お知らせ • Jun 28Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023Euglena Co., Ltd. announced that they will report Q2, 2023 results on Aug 14, 2023
Reported Earnings • May 17First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥1.45 loss per share. Net loss: JP¥167.0m (flat on 1Q 2022). Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year.
Reported Earnings • Mar 31Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Revenue is forecast to stay flat during the next 3 years compared to a 4.1% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 12% per year.
Price Target Changed • Mar 24Price target increased by 11% to JP¥1,000Up from JP¥900, the current price target is provided by 1 analyst. New target price is 10% above last closing price of JP¥906. Stock is up 10% over the past year. The company is forecast to post a net loss per share of JP¥11.50 next year compared to a net loss per share of JP¥23.83 last year.
お知らせ • Feb 16Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023Euglena Co., Ltd. provided consolidated earnings guidance for the fiscal year ending Dec. 31, 2023. The company expects net sales to be JPY 45,000 million.
お知らせ • Feb 15Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023.
Reported Earnings • Feb 14Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)Full year 2022 results: JP¥23.83 loss per share (improved from JP¥44.51 loss in FY 2021). Revenue: JP¥44.4b (up 46% from FY 2021). Net loss: JP¥2.67b (loss narrowed 43% from FY 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 08Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.On February 6, 2023, Euglena Co., Ltd. closed the transaction.
お知らせ • Jan 20Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.Euglena Co., Ltd. announced that it will issue 3,208,500 common shares at a price of ¥935 for gross proceeds of ¥2,999,947,500 and 48 convertible bond-type bonds with stock acquisition rights at a price of ¥100,000,000 for gross proceeds of ¥4,800,000,000 for aggregate gross proceeds of ¥4,785,000,000 on January 19, 2023. The transaction will include participation from Marui Group Co., Ltd. of 2,139,000 shares and Rohto Pharmaceutical Co.,Ltd. of 1,069,500 shares post completion of the transaction. The company is issuing securities through third party allotment. The 10th stock acquisition rights are convertible into 5,133,689 shares. The transaction is expected to close on February 6, 2023. The transaction has been approved by the board of directors of the company.
お知らせ • Dec 28Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023Euglena Co., Ltd. announced that they will report fiscal year 2022 results on Feb 13, 2023
Reported Earnings • Apr 02Full year 2021 earnings released: JP¥39.26 loss per share (vs JP¥17.15 loss in FY 2020)Full year 2021 results: JP¥39.26 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥27.5b (up 97% from FY 2020). Net loss: JP¥4.03b (loss widened 153% from FY 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥44.51 loss per share (down from JP¥17.15 loss in FY 2020). Revenue: JP¥30.5b (up 118% from FY 2020). Net loss: JP¥4.68b (loss widened 194% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 17Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥3.83b (up 34% from 2Q 2020). Net income: JP¥164.0m (up 51% from 2Q 2020). Profit margin: 4.3% (up from 3.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 16New 90-day high: JP¥1,264The company is up 58% from a price of JP¥799 on 16 December 2020. Outperformed the Japanese market which is up 10.0% over the last 90 days. Exceeded the Personal Products industry, which is flat over the same period.
Reported Earnings • Feb 17First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥3.91b (up 22% from 1Q 2020). Net loss: JP¥360.0m (loss widened 43% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 05New 90-day high: JP¥909The company is up 4.0% from its price of JP¥871 on 06 November 2020. The Japanese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 2.0% over the same period.
Reported Earnings • Dec 27Full year 2020 earnings released: JP¥16.00 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: JP¥13.3b (down 4.7% from FY 2019). Net loss: JP¥1.49b (loss narrowed 85% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 23New 90-day low: JP¥774The company is down 16% from its price of JP¥917 on 24 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Dec 07New 90-day low: JP¥797The company is down 4.0% from its price of JP¥830 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.
